pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-19b-1 |
Genomic Coordinates | chr13: 91351192 - 91351278 |
Synonyms | MIRN19B1, miR-19b-1, miRNA19B1, MIR19B1 |
Description | Homo sapiens miR-19b-1 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-mir-19b-2 |
Genomic Coordinates | chrX: 134169671 - 134169766 |
Synonyms | MIRN19B2, miR-19b-2, MIR19B2 |
Description | Homo sapiens miR-19b-2 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-19b-3p | ||||||||||||||||||
Sequence | 54| UGUGCAAAUCCAUGCAAAACUGA |76 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | BMPR2 | ||||||||||||||||||||
Synonyms | BMPR-II, BMPR3, BMR2, BRK-3, POVD1, PPH1, T-ALK | ||||||||||||||||||||
Description | bone morphogenetic protein receptor type 2 | ||||||||||||||||||||
Transcript | NM_001204 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on BMPR2 | |||||||||||||||||||||
3'UTR of BMPR2 (miRNA target sites are highlighted) |
>BMPR2|NM_001204|3'UTR 1 AATGTTTTCAAGCCTATGGAGTGAAATTATTTTTTGCATCATTTAAACATGCAGAAGATGTTTAAAAATAAAAAAAAAAC 81 TGCTTTATCCTCCTGTCAGCACCCCCTCCCACCCCTGCAACAAAGACTTGCTTTAAATAGATTTCAGCTATGCAGAAAAA 161 TTTAGCTTATGCTTCCATATTTTTAAATTTTGTTTTTTAAGTTTTGCACTTTTGTTTAGTCTCGCTAAAGTTATATTTGT 241 CTGTTATGACCACAGAGTTATATGTGTGTGTATCAAAAGTGGTCTCAAAATATTTTTTTAAGAAAAAAAGCAAAAACAAT 321 GTATTGCTGATAATCAGTTTGGACCAGTTTCTTAAGGTCATTAAAACAGAAGCAAATTAAGACAGGTTTGACTGCAGTGG 401 TGTCTGGTATCCATGTTTTATTTCTGGGCACAAGCTAGTTTTTATGTTGATACGTTCCTGAACATATTATCTTGTTGGAC 481 ATCTTTTCTCTTGTGTTTTGTTTGAATGTGCAATAGTTTATAGGCCACAAATAAGCTTTCTTGTAAGCTCTCTTCCTAAC 561 AGGGCACATATTCTTCCATAATATAAACACTTTTCTGCCCCATCTCCCATACTTTTGAAGGTCAGTTCTATGACAGTGAA 641 TTTTGCACAGGAGAAGCAGCTACCTGATTTCTTACTTTCTCTCTCCTTATCATGGAGAATACAGAAACATTGTCTGAAAG 721 GGCTCTAAAGAAGGAACTACCAAAACCTGACTTGAAATGCCATTTCTTTTAACCTTCCAAATCCTAAATGTTTCCTTCAA 801 GGCATCTTAATAAACTTATTTGCTTCTGGTTTTGGGAGTTCATAAGAGAGAATAGAACAAAATACAGGACATCAAATATT 881 AGCCATTTCCCATTTTATTTTATTTTTCTATGTAGGTTCATGTTCCATGTTCATTTATTTAAGAAATACATTTTTATTGG 961 TAAGCTTATAGAGCTACACTTATGGAATTTTTAAGTAGGTAAATAAATGGTTAAGACAAAATAGTGTTATAGCCTTCATT 1041 CTCTGAATAGGCCATCTTTGACTCATAAAATTACCCTTACTGTTTATTATAACTTCAGAAGTAATTTATAGTTCTGAACC 1121 TATAGTATCTTTTACCCTGTTCCCAAGCAAAGACTGGTGACTTTATCTGAAAATGATTCCTCTTCCCATGACCTAAAACA 1201 CTGTGAGGAAAAATCATTCAAGTGGCATGCCAAGTCCCTATGAAGGAAGGGCTGCTATCAAACCTACCTTTTTTGAGCAA 1281 ACTGAGACTAAACTTCTCTCTTTTCAAAATTGTGTTATCTTCCTTAATCCTATTTTCATAATTTTTCCTTTTGCCAGTTT 1361 TTCACATTATCTTTGATATGTGAGCAACATTTATTATTTACATTAGAGTATACCTTTTAGTAATAAAATGACTTGAAATC 1441 ATATTATTTTTAAAAGCCCTTTGCTTCTTTCATTACTTATAATCTCCTCTAAAACAACCTCTGCATGTTTTTTTTAAATA 1521 AAGCACTTTCTGTCAAATAATGGACTTTTTTCTAAACAGAAATTATTTTCTATTAATTTGCAAACTGATGATTTCACTTT 1601 TTTTTACTTTTTTTTCGATTATCAGAGTACTTAGTAAATGTTATATAGTTTAGTTCTAAGATAGTTCCAGGGATTAAAAG 1681 GTTAAGAGGAAAACACAAATCACCAAATTTCTGATTTATGTTTTTATCTCCTGAACAATATTTTCTCACTCATATTCCTC 1761 TATCTTATCACTTAGCTAAAGACAGCCTAAATTTCCCAATTTTCTGTCCAAAATATTTGTGATTTACTTGTATATAAGCC 1841 TTCTCATTTGCCATGTGCTGTGATCTTACAAGTTAGATGTTACTATACCTACCATTTATTCAGCTGGATTGCTGAACACA 1921 GTTCTGGATTCATAGAATTAAGAATATCTTGTTAGTGCCCAGGATTTCCACGTTTTGTGTTTTATTGGCCCTTTTCTTTA 2001 TTCAGCCCCTTAATCTATTTTCAGTCTTCTGGCACGTAATTTTTTTCACAGTTATTATTCTTCTATTAACAAATTATTTT 2081 TATCTTTCCTAGTACATTTTCACTTAGTTCTCTTGCCCTTAAATATCTTTCACATGCATTTTAGGATATTCTTTTCAAAT 2161 ATTTGTAGGACAACTTTGAATCAAAATAAATTATGTTCCTTCTCCAATTTGAAGCATTGAGGATAAATGACCATTTGAGG 2241 TCTAACTGATCTTTTCCTGCCAGAAGAGTTATCTTACGTTCTGCTATATTTGTATTTGGGCCAGTTGATTGTAGGTTGTC 2321 CAACATTTTTTAATATTGGGAAAATTATGATAAAATGCTTTAAAAATTAATATGCCAGATTAAAATAACTGAATAGTTTA 2401 CTATTTCATTCAAGCATGTTTAAAACAAATAATTTCCTTTCACCAGTTTTTCTTAGTAAACTCCTGAAAAAGTAGGAAAG 2481 GTGGAAAGTATATATCATTTTTATAAATTTTAAATTGTACATCAGACTTTTAAAATCTGTAATATACAAGCAAGCAAAAT 2561 TATTTTAAATGACTTAATTGTATGCTAATACTCATCTGATAATAAATGCTTCTTAAAGTTGACATTTAACTGCTATCACA 2641 AAGTTTTATATGTAGAAAAGTGGGGTCCTTTTGAATAAAAGATCATTCAACTAAAAATATTAAAATTTATTTCACTGGAT 2721 GGTAATGTAACCTTAAAAGCATCATAATAGGTAAAGTCTAATATTAGTTCCCTTAACAAAATCCTAACTGTATACCAGAA 2801 TTAGGTCACTGAAAGAACTTGATTTGAATTACGTTTAGACAAAAATGATTTAATTGTAAATTCTTAAAACTTTCTAAATG 2881 CATAATTGGCAAAAAAAAAAACCCACTGTTACCAGTGTAGGAAGTTACAAGAAGGCACATACTGAATGCTGAAGTATACA 2961 TATGCTATTTCTCTTAAACCTCAGAGCAACCATATGAGCATTGTAATTAATATTCCCATTTTACAGATGAGGAAACTGAA 3041 GCTAAGAGAAGCTAAGTAATATGCCCAAGGTCCACATCTAGTAACAGACAAAGCTGGGATTTCAGTCTATGTCTGCCTCT 3121 CTCCACATCTCTTTCATCCATACCACACTGCCTACATGCCATATGACAGGATGTGTAATGGGCTAACGTTTATTTAAAAA 3201 GTTCAGGCCAGGTGCAGTGGCTTATGCCTATAATCCCCGCACTTTGGGAGGCCGAGCCGGGTGGATCATGAGGTCAGACG 3281 TTCAACACCAGCCTGGCCAAGATGGTGAAACCCCGTCTCTATTAAAAATATTTTTTAAAAATTAACTGAGCGTGGTGGTG 3361 GGCGCCTGTAGTCCCAGCTACTCAGGAGGCTAAGGCAGGAGAATCTCTTGAACCCGAGAGGTGGAGGTTGCAGTGAGCTG 3441 AGATCGCGCCACTGCACTGCAGCCTAGGCGACAGAGCAAGACTGCCTCAAAAAAAAAACATAAAAATTCAGTCACTATAC 3521 TCTGGCACAATTTTCATTTGTATATGAGCCAAACCACATACCTTAATGATTTGGGAAGTTAGGCAAATATGAGATATGTA 3601 GACATATCTATGCTGATTGTTGCTTGAGAAATAATTACTAATTCTAGACAAAACTCAATCCTGTATCTTCCATCATGAAT 3681 CTTAAAATCATTTCACTTCACTCCTAACATTTCTTACATTGCAGAACTAATGGTAAAGTAAATTTTACGGAAAAAGTTAA 3761 GATAGCTTTGGGAACAGAGACCTTTCCCTAAATTGATTCCATAGCAGATTTGGGGGAATTAACAAAGAATTTCAGTCTCA 3841 TCAATCCTTTGAATCCATCTTCAAAACTTCTGCTTTTAATAACTTTAGAAAATTTACTAATCTATAGAACTAATTGAGTA 3921 GGATATAGGAAGGATACAAGGATATAATGTCCTTTTTATAAAAGTTTAGTATAGCTTCTTTACATGTATCCACTTGTTCC 4001 AGAAAATGTGCATTGGTTCTGAATGTGAAAATATTTAAAGAGAGAAAGGAACACTCAAGTAAGTGTGGGCTTCAGTGGGA 4081 ATTATCACAAAACATTGGCAAGTATTTTTATTTAAATTATTTTCAAATTTGACTTCTACAGCCAAGTGGAATTGGTAGGC 4161 TGTAGCTGTTACACTGAAATTTCTAGTCTTTGTAAGTGCCTCCTGAAAGTCATTTAAAATGGAAAAATATTTCAATGAGC 4241 TTTTCCTTTTTTCATATTTATGGACATGAATATTTTATTGGAGATCATTAACTCCTAGAATTTGAGATTATATTTCCATA 4321 CAACATTTTATAAAGTTATGTTGAACTTACTACCTGTTATGTGCAGGTTATTATGTAACTATTCACAGATTGCTTCATAT 4401 ATTGCTTTATCTTCCCATCTAACTTCTTAAAGTTAAAATCCGGACACACATGTTGATTATCTAGACCAGTCATTCTGGAA 4481 ATTGTAACACTCCCACATAAACCCCAGGAGACTTTTTCAGAATGCAATGTTTCTAAATGTACTGTTACTGGCAGTTTACT 4561 CTCCAGCATATAAGGTTGCATTTTAACTTTTAGATTATGAACTGTGCAAACTTTACCCAAAACTATCTTGCATGATTCCC 4641 TCCTAAATATATTCCTTGATTAAGTAAATCTGGCAAATCACTGTTTGAGCTAGTTACATAAAATTTGTTATCAAGAGAAG 4721 GCTTTTCTACAAGTTTCCAGATTAACATAAAGAAAAGAGGGAATCACAGGGCATTTAAGTGCACCTTCCCATTACTTTCC 4801 TTAAATCACCTCATAGTTAGGCTGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGTGGATC 4881 ACGAGGTCAGGGGACTGAGATCATCCTGGCTAACACGATGAAACCTCATCTCTACTAAAAATACAAATAATTAGCCAGGC 4961 ATGGTGGCACGCGCCTGTAGTCCCAGCTACTCGGGAGGCAGAGACAGGAGAATCGTTTGCACCCGGGAGGCGGAGGTTGT 5041 TGCAGTGAGCCGAGATCGCGCCAATGCACTCCAGCCTGGGCTACAGAGTGAGACTCCATCTCAAAAAAAAACAAAAAAAA 5121 TCACCTCATAGTTTATGTCTGACTTACTCCAAACCTCAGTTATCTGATTTGTAGTCTGTGTCAGGAAAGTTTTCTTCATA 5201 TCTATTCTGTCTCCCTCCTCTTTGATTTTAAATTTTTTTCTTTTACCCAGTAGGACAAAAAAGAGCAGTTGGTCATCATC 5281 CCCAATATTCTTAGTCTTCAGTATGCTTCAGGCCTCTCAATGAACACTTAAGTCTCAATTCTTCAGACAAAATTGCTTAA 5361 GCTCTTCTCCTCAGTCCTATTTTAATGACTTTATATTTAAGAATATAGAATTATATTTTCTTTTATATTCAAATTCATTA 5441 CTCCAGTTAAGTAATAGTTTGATAGTTTGATAGAATCGAGAGTTAAGATGTTTCTATTTGAAAGTGGATTCAACCATCAG 5521 ACCACCAGCAAATCGGCACTTAATTTTTGTGTTATCTAACATTTTCTATTGTGGAATTTTATGATTTTATATTCTCATTA 5601 GTTATAACTAAAAAGCCATGCACACAGAATTGTATATCATTTTGCCATTAAAATTTTTTAACATATTGCAGCAAGCTTAG 5681 TTTTATGATTGAGCCACAACCTTTTACATATTTTTTGTATGAAATATTAAACACTAAATGCAAGATTAACTTTCAAAAGC 5761 AAACCCTACATTAATCAGGTATTATCTATGGACATTTTTGTAGACCACTTTTGAAATACTTATTATTTTGCAACATAGAC 5841 TGGACTATACAACTTTCATTTAACTTTTAGGTGACTGATTTAAGTTGAGTGTGCATATAGAGAAAAACCTAGAAATTTAT 5921 CTCATGGCAGATACATTTGAAAGTACTTCAGAAGAATTTATGCTGTATATTAAAACTAGGCTCAAAATAAATCTATCGTA 6001 TCTTTAAAAGTCCAATTCTGTTATTACTGTGATGTTTGTAGTGTTACTATTAAACATTGTGAACATACACATTTTTAAAA 6081 CAACTTGAAACCCATTTTAAAATCTGGGTAAGAGAGAAGGAATCTTCAGAACAAAATCACATCATTAGGGTGTCCAGTTT 6161 ATGATTGAATTTTTAAGCAAATTACTGTATTTGAAACTACAACTTGATTTGGTTTTCAGTTTTAAAAGGCAACATGTGGG 6241 TTTTATCCATTTTATTTATACCTTTAGATTTCAGAAACATCTTCATGTTTTAGATGCATTCTACAGACATCATGTTACTT 6321 AAAAACTCAGGGCCCCTTTCATCCCTTTGTACACTGAAAAAGTTCAATTGTTAGCAAGTAAGCAATTAGATCCAGTTGAA 6401 TATTTAAAGTGTTTGTTGCACAGTTCATTTAATGTTTCATCTTATTTGACTTTTTCACATAGATATAATATCAGATTTCA 6481 TTAATTATAAAAAGTTGCCCAGTTCTGTAATTACTGAACAGAGGGAATGACTCAACTAATTGGCTACATGTTGCAACAAA 6561 TTTAGGCCTTTAGAGTTGAAGCACTGACTTAAAACGACTTACATTTCTGTTCTTTGGTCAAATGACCATACATGATATGG 6641 GACAAATTGTTTCATTTTGTTTGTTTTTTAATAAGGGAACTTGGTAAAGTAGTTCCTGTCAGATAGGATTTTCTCAAGAG 6721 ACAATTTAACGTTATAAAGCCTTCTAAAAGTGAACTAAATATTTTATAACTTTAGTAATAGCTTGGATGGTTTTGAGAAA 6801 ATAACCTGTATTTATCACATTGTCAAACAGAATTTTTCTTTGAATCAGACAAGTTCAAGCTCTAAATTGATGTGCTATAT 6881 ACTTAAAATCCTAGGAAGTTATCTGTAACCAGTCTCTTGTCTCAGGCTCTTCACCTTGTTACCAATCCTCGTAAGTATGT 6961 AAAGGAAACATATTTTTAAAGAAGCTTAACAGTAAGAAAAAATTACTAAAAGATGCAATTCAAAGATAGGTCCCAGTTTA 7041 ACACTGAATTGCTTGACTTCTGTGGCTTTTCTTTTTCTGGCCACATTTATTTATTTAAGCAATTTTTGTATGCCTTGTTA 7121 TTTCATTTCCATAGAGATTATATTGTATCAGTGTTTATGTAAGCTGGAATCATCCTCAGTTTTTTGCTGATAATTTTTCA 7201 AATAAAGATACATGGATAATTGTAAAATACACTAACTCTTAGGGTGTTGTAGTAGCTGAAACATGGAGATGCGTAGCTGT 7281 CATGCTTTTTCTGAATGGACAGGAGAAACATAAGCTACGGAGTATTCACTTCTGAGGATGCTTTTCCGGAAAAAGAAAGG 7361 CTAGAAAATACTCGCACTTCCTCAGAACCCTCTTTCTTGTTAACGGGTATCTTTTGTTGGTGTGTTTTGCTCTTACATTA 7441 CAGATAGACTATCATATATGACTTTATGAATAATTTCAGTTATTTTGCTTTTGTATAAGCTGTCTGAAGCCTTGCTATGC 7521 TGTATAAGTTGTGTTTGATGGATCAGTGTGAGTATAAAATAAAGCAAATCACTTTTCTTTTGTATTATCTATGGATGCCA 7601 CTATGAAAGCTGACATTAAGCCACTAAAGAGTTTTCTATGAATAAGTGTAAGTAAATGCTTTGATATATATAAACCTAAA 7681 TAAAAAGATTGTATTGATACAGAGACATTGGAGAAGGAGATTTTAAGGCAGTTCTTTAGGTTTAAAAAGGCTTGCTGTAA 7761 AATGGTGCGTTATTCCGTTTATTAAAGATCATATTAATGACAATAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 , HepG2 |
Disease | 659.0; |
Location of target site | 3'UTR |
Tools used in this research | TargetScan |
Original Description (Extracted from the article) |
...
"Ectopic overexpression of miR-17/92 resulted in a strong reduction of the BMPR2 protein
... - Brock M; Trenkmann M; Gay RE; Michel BA; et al., 2009, Circulation research. |
Article |
- Brock M; Trenkmann M; Gay RE; Michel BA; et al. - Circulation research, 2009
Dysregulated expression of bone morphogenetic protein receptor type II (BMPR2) is a pathogenetic hallmark of pulmonary hypertension. Downregulation of BMPR2 protein but not mRNA has been observed in multiple animal models mimicking the disease, indicating a posttranscriptional mechanism of regulation. Because microRNAs (miRNAs) regulate gene expression mainly through inhibition of target gene translation, we hypothesized that miRNAs may play a role in the modulation of BMPR2. Performing a computational algorithm on the BMPR2 gene, several miRNAs encoded by the miRNA cluster 17/92 (miR-17/92) were retrieved as potential regulators. Ectopic overexpression of miR-17/92 resulted in a strong reduction of the BMPR2 protein, and a reporter gene system showed that BMPR2 is directly targeted by miR-17-5p and miR-20a. By stimulation experiments, we found that the miR-17/92 cluster is modulated by interleukin (IL)-6, a cytokine involved in the pathogenesis of pulmonary hypertension. Because IL-6 signaling is mainly mediated by STAT3 (signal transducer and activator of transcription 3), the expression of STAT3 was knocked down by small interfering RNA, which abolished the IL-6-mediated expression of miR-17/92. Consistent with these data, we found a highly conserved STAT3-binding site in the promoter region of the miR-17/92 gene (C13orf25). Promoter studies confirmed that IL-6 enhances transcription of C13orf25 through this distinct region. Finally, we showed that persistent activation of STAT3 leads to repressed protein expression of BMPR2. Taken together, we describe here a novel STAT3-miR-17/92-BMPR2 pathway, thus providing a mechanistic explanation for the loss of BMPR2 in the development of pulmonary hypertension.
LinkOut: [PMID: 19390056]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Jiyoye |
Tools used in this research | TargetScan |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in Supplenentary. RNA binding protein: AGO2.
... - Riley KJ; Rabinowitz GS; Yario TA; Luna JM; et al., 2012, The EMBO journal. |
Article |
- Riley KJ; Rabinowitz GS; Yario TA; Luna JM; et al. - The EMBO journal, 2012
Epstein-Barr virus (EBV) controls gene expression to transform human B cells and maintain viral latency. High-throughput sequencing and crosslinking immunoprecipitation (HITS-CLIP) identified mRNA targets of 44 EBV and 310 human microRNAs (miRNAs) in Jijoye (Latency III) EBV-transformed B cells. While 25% of total cellular miRNAs are viral, only three viral mRNAs, all latent transcripts, are targeted. Thus, miRNAs do not control the latent/lytic switch by targeting EBV lytic genes. Unexpectedly, 90% of the 1664 human 3'-untranslated regions targeted by the 12 most abundant EBV miRNAs are also targeted by human miRNAs via distinct binding sites. Half of these are targets of the oncogenic miR-17 approximately 92 miRNA cluster and associated families, including mRNAs that regulate transcription, apoptosis, Wnt signalling, and the cell cycle. Reporter assays confirmed the functionality of several EBV and miR-17 family miRNA-binding sites in EBV latent membrane protein 1 (LMP1), EBV BHRF1, and host CAPRIN2 mRNAs. Our extensive list of EBV and human miRNA targets implicates miRNAs in the control of EBV latency and illuminates viral miRNA function in general.
LinkOut: [PMID: 22473208]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | SAOS-2 |
Disease | 659.0; |
Location of target site | 3'UTR |
Tools used in this research | TargetScan |
Original Description (Extracted from the article) |
...
"Mutations in the miR-17 and miR-19a predicted binding sites of the Bmpr2 3 -UTR caused a derepression of luciferase activity
... - Murphy BL; Obad S; Bihannic L; Ayrault O; et al., 2013, Cancer research. |
Article |
- Murphy BL; Obad S; Bihannic L; Ayrault O; et al. - Cancer research, 2013
Medulloblastoma, originating in the cerebellum, is the most common malignant brain tumor in children. Medulloblastoma consists of four major groups where constitutive activation of the Sonic Hedgehog (SHH) signaling pathway is a hallmark of one group. Mouse and human SHH medulloblastomas exhibit increased expression of microRNAs encoded by the miR-17~92 and miR-106b~25 clusters compared with granule progenitors and postmitotic granule neurons. Here, we assessed the therapeutic potential of 8-mer seed-targeting locked nucleic acid (LNA)-modified anti-miR oligonucleotides, termed tiny LNAs, that inhibit microRNA seed families expressed by miR-17~92 and miR-106b~25 in two mouse models of SHH medulloblastomas. We found that tumor cells (medulloblastoma cells) passively took up 8-mer LNA-anti-miRs and specifically inhibited targeted microRNA seed-sharing family members. Inhibition of miR-17 and miR-19a seed families by anti-miR-17 and anti-miR-19, respectively, resulted in diminished tumor cell proliferation in vitro. Treatment of mice with systemic delivery of anti-miR-17 and anti-miR-19 reduced tumor growth in flank and brain allografts in vivo and prolonged the survival of mice with intracranial transplants, suggesting that inhibition of the miR-17~92 cluster family by 8-mer LNA-anti-miRs might be considered for the treatment of SHH medulloblastomas.
LinkOut: [PMID: 24145352]
|
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
708 hsa-miR-19b-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT001164 | NR3C2 | nuclear receptor subfamily 3 group C member 2 | 1 | 1 | ||||||||
MIRT001793 | BACE1 | beta-secretase 1 | 2 | 1 | ||||||||
MIRT003371 | PTEN | phosphatase and tensin homolog | 7 | 7 | ||||||||
MIRT003780 | ATXN1 | ataxin 1 | 5 | 3 | ||||||||
MIRT004064 | HIPK3 | homeodomain interacting protein kinase 3 | 3 | 2 | ||||||||
MIRT004065 | ARID4B | AT-rich interaction domain 4B | 3 | 2 | ||||||||
MIRT004066 | MYLIP | myosin regulatory light chain interacting protein | 2 | 1 | ||||||||
MIRT004309 | ESR1 | estrogen receptor 1 | 4 | 1 | ||||||||
MIRT004310 | NCOA3 | nuclear receptor coactivator 3 | 2 | 1 | ||||||||
MIRT004335 | KAT2B | lysine acetyltransferase 2B | 3 | 1 | ||||||||
MIRT004336 | SOCS1 | suppressor of cytokine signaling 1 | 5 | 6 | ||||||||
MIRT004523 | BCL2L11 | BCL2 like 11 | 2 | 2 | ||||||||
MIRT004594 | TGFBR2 | transforming growth factor beta receptor 2 | 7 | 10 | ||||||||
MIRT004933 | BMPR2 | bone morphogenetic protein receptor type 2 | 5 | 3 | ||||||||
MIRT006476 | CUL5 | cullin 5 | 2 | 1 | ||||||||
MIRT006647 | TLR2 | toll like receptor 2 | 3 | 1 | ||||||||
MIRT006742 | PRKAA1 | protein kinase AMP-activated catalytic subunit alpha 1 | 2 | 3 | ||||||||
MIRT006743 | PPP2R5E | protein phosphatase 2 regulatory subunit B'epsilon | 3 | 3 | ||||||||
MIRT007271 | CYP19A1 | cytochrome P450 family 19 subfamily A member 1 | 1 | 1 | ||||||||
MIRT007272 | GCM1 | glial cells missing homolog 1 | 1 | 1 | ||||||||
MIRT031084 | CTGF | connective tissue growth factor | 1 | 1 | ||||||||
MIRT031085 | HMGCS1 | 3-hydroxy-3-methylglutaryl-CoA synthase 1 | 1 | 1 | ||||||||
MIRT031086 | ZNF417 | zinc finger protein 417 | 1 | 1 | ||||||||
MIRT031087 | ZNF567 | zinc finger protein 567 | 1 | 1 | ||||||||
MIRT031088 | MRPL19 | mitochondrial ribosomal protein L19 | 1 | 1 | ||||||||
MIRT031089 | RPA2 | replication protein A2 | 1 | 1 | ||||||||
MIRT031090 | HOXC8 | homeobox C8 | 1 | 1 | ||||||||
MIRT031091 | KCTD20 | potassium channel tetramerization domain containing 20 | 1 | 1 | ||||||||
MIRT031092 | NDEL1 | nudE neurodevelopment protein 1 like 1 | 1 | 1 | ||||||||
MIRT031093 | THOP1 | thimet oligopeptidase 1 | 1 | 1 | ||||||||
MIRT031094 | SESTD1 | SEC14 and spectrin domain containing 1 | 1 | 1 | ||||||||
MIRT031095 | DYNLL2 | dynein light chain LC8-type 2 | 1 | 1 | ||||||||
MIRT031096 | SMCR8 | Smith-Magenis syndrome chromosome region, candidate 8 | 1 | 1 | ||||||||
MIRT031097 | RASSF1 | Ras association domain family member 1 | 1 | 1 | ||||||||
MIRT031098 | RAB5B | RAB5B, member RAS oncogene family | 2 | 9 | ||||||||
MIRT031099 | HHEX | hematopoietically expressed homeobox | 1 | 1 | ||||||||
MIRT031100 | ELOVL4 | ELOVL fatty acid elongase 4 | 1 | 1 | ||||||||
MIRT031101 | PALLD | palladin, cytoskeletal associated protein | 1 | 1 | ||||||||
MIRT031102 | MOSPD2 | motile sperm domain containing 2 | 1 | 1 | ||||||||
MIRT031103 | ANKRD10 | ankyrin repeat domain 10 | 1 | 1 | ||||||||
MIRT031104 | RAB34 | RAB34, member RAS oncogene family | 2 | 3 | ||||||||
MIRT031105 | YTHDC1 | YTH domain containing 1 | 1 | 1 | ||||||||
MIRT031106 | KATNAL1 | katanin catalytic subunit A1 like 1 | 1 | 2 | ||||||||
MIRT031107 | NACC2 | NACC family member 2 | 2 | 4 | ||||||||
MIRT031108 | ARHGAP12 | Rho GTPase activating protein 12 | 2 | 5 | ||||||||
MIRT031109 | CENPN | centromere protein N | 1 | 1 | ||||||||
MIRT031110 | PRKACB | protein kinase cAMP-activated catalytic subunit beta | 2 | 3 | ||||||||
MIRT031111 | LPGAT1 | lysophosphatidylglycerol acyltransferase 1 | 1 | 1 | ||||||||
MIRT031112 | SIX4 | SIX homeobox 4 | 1 | 1 | ||||||||
MIRT031113 | SLAIN1 | SLAIN motif family member 1 | 1 | 1 | ||||||||
MIRT031114 | HIPK1 | homeodomain interacting protein kinase 1 | 5 | 2 | ||||||||
MIRT031115 | DNAJA2 | DnaJ heat shock protein family (Hsp40) member A2 | 1 | 1 | ||||||||
MIRT031116 | TRIM2 | tripartite motif containing 2 | 1 | 1 | ||||||||
MIRT031117 | DMXL2 | Dmx like 2 | 1 | 2 | ||||||||
MIRT031118 | CCNL1 | cyclin L1 | 2 | 8 | ||||||||
MIRT031119 | SECISBP2L | SECIS binding protein 2 like | 2 | 5 | ||||||||
MIRT031120 | PATL1 | PAT1 homolog 1, processing body mRNA decay factor | 2 | 7 | ||||||||
MIRT031121 | TES | testin LIM domain protein | 1 | 1 | ||||||||
MIRT031122 | ATM | ATM serine/threonine kinase | 1 | 1 | ||||||||
MIRT031123 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 1 | 1 | ||||||||
MIRT031124 | NR3C1 | nuclear receptor subfamily 3 group C member 1 | 1 | 1 | ||||||||
MIRT031125 | LRIG3 | leucine rich repeats and immunoglobulin like domains 3 | 1 | 1 | ||||||||
MIRT031126 | SNAPIN | SNAP associated protein | 1 | 1 | ||||||||
MIRT031127 | LRP8 | LDL receptor related protein 8 | 1 | 1 | ||||||||
MIRT031128 | EGLN3 | egl-9 family hypoxia inducible factor 3 | 1 | 1 | ||||||||
MIRT031129 | XYLT2 | xylosyltransferase 2 | 1 | 1 | ||||||||
MIRT031130 | ADRM1 | adhesion regulating molecule 1 | 2 | 3 | ||||||||
MIRT031131 | NDUFB2 | NADH:ubiquinone oxidoreductase subunit B2 | 1 | 1 | ||||||||
MIRT031132 | TRPC3 | transient receptor potential cation channel subfamily C member 3 | 2 | 4 | ||||||||
MIRT031133 | SLC44A1 | solute carrier family 44 member 1 | 1 | 1 | ||||||||
MIRT031134 | BAHD1 | bromo adjacent homology domain containing 1 | 1 | 1 | ||||||||
MIRT031135 | SGTB | small glutamine rich tetratricopeptide repeat containing beta | 1 | 1 | ||||||||
MIRT031136 | PDZD11 | PDZ domain containing 11 | 1 | 1 | ||||||||
MIRT031137 | SEC23B | Sec23 homolog B, coat complex II component | 1 | 1 | ||||||||
MIRT031138 | TBC1D4 | TBC1 domain family member 4 | 1 | 1 | ||||||||
MIRT031139 | TBC1D25 | TBC1 domain family member 25 | 1 | 1 | ||||||||
MIRT031140 | HARS | histidyl-tRNA synthetase | 1 | 1 | ||||||||
MIRT031141 | COX10 | COX10, heme A:farnesyltransferase cytochrome c oxidase assembly factor | 2 | 8 | ||||||||
MIRT031142 | MAPRE3 | microtubule associated protein RP/EB family member 3 | 1 | 1 | ||||||||
MIRT031143 | SUV420H1 | lysine methyltransferase 5B | 1 | 1 | ||||||||
MIRT031144 | CDK19 | cyclin dependent kinase 19 | 1 | 1 | ||||||||
MIRT031145 | KCTD10 | potassium channel tetramerization domain containing 10 | 2 | 5 | ||||||||
MIRT031146 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | 1 | 1 | ||||||||
MIRT031147 | MAP7 | microtubule associated protein 7 | 1 | 1 | ||||||||
MIRT031148 | CSNK1G1 | casein kinase 1 gamma 1 | 1 | 1 | ||||||||
MIRT031149 | WDR33 | WD repeat domain 33 | 1 | 1 | ||||||||
MIRT031150 | PDRG1 | p53 and DNA damage regulated 1 | 2 | 10 | ||||||||
MIRT031151 | PSMD9 | proteasome 26S subunit, non-ATPase 9 | 1 | 1 | ||||||||
MIRT031152 | OTUD4 | OTU deubiquitinase 4 | 1 | 2 | ||||||||
MIRT031153 | ZCCHC14 | zinc finger CCHC-type containing 14 | 1 | 1 | ||||||||
MIRT031154 | DERL1 | derlin 1 | 1 | 1 | ||||||||
MIRT031155 | ATP6V1C1 | ATPase H+ transporting V1 subunit C1 | 1 | 1 | ||||||||
MIRT031156 | SMAD4 | SMAD family member 4 | 3 | 7 | ||||||||
MIRT031157 | TMEM9B | TMEM9 domain family member B | 1 | 2 | ||||||||
MIRT031158 | ZMYM2 | zinc finger MYM-type containing 2 | 1 | 1 | ||||||||
MIRT031159 | GMEB2 | glucocorticoid modulatory element binding protein 2 | 1 | 1 | ||||||||
MIRT031160 | CD46 | CD46 molecule | 4 | 2 | ||||||||
MIRT031161 | AP3S2 | adaptor related protein complex 3 sigma 2 subunit | 2 | 2 | ||||||||
MIRT031162 | CA13 | carbonic anhydrase 13 | 1 | 1 | ||||||||
MIRT031163 | MID1IP1 | MID1 interacting protein 1 | 2 | 8 | ||||||||
MIRT031164 | POGZ | pogo transposable element derived with ZNF domain | 2 | 3 | ||||||||
MIRT031165 | TRIM59 | tripartite motif containing 59 | 1 | 1 | ||||||||
MIRT031166 | ABHD5 | abhydrolase domain containing 5 | 2 | 6 | ||||||||
MIRT031167 | SLC35D1 | solute carrier family 35 member D1 | 1 | 1 | ||||||||
MIRT031168 | PPP6R2 | protein phosphatase 6 regulatory subunit 2 | 1 | 1 | ||||||||
MIRT031169 | PPP1R15B | protein phosphatase 1 regulatory subunit 15B | 2 | 10 | ||||||||
MIRT031170 | ZNF217 | zinc finger protein 217 | 1 | 2 | ||||||||
MIRT031171 | ZNF644 | zinc finger protein 644 | 2 | 3 | ||||||||
MIRT031172 | FBXO28 | F-box protein 28 | 2 | 4 | ||||||||
MIRT031173 | SOGA1 | suppressor of glucose, autophagy associated 1 | 1 | 1 | ||||||||
MIRT031174 | MPHOSPH9 | M-phase phosphoprotein 9 | 1 | 1 | ||||||||
MIRT031175 | ZNF721 | zinc finger protein 721 | 1 | 2 | ||||||||
MIRT031176 | PAPD4 | poly(A) RNA polymerase D4, non-canonical | 2 | 3 | ||||||||
MIRT031177 | ZNF711 | zinc finger protein 711 | 1 | 1 | ||||||||
MIRT031178 | MB21D2 | Mab-21 domain containing 2 | 2 | 3 | ||||||||
MIRT031179 | ROR1 | receptor tyrosine kinase like orphan receptor 1 | 1 | 1 | ||||||||
MIRT031180 | ENPP5 | ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative) | 2 | 3 | ||||||||
MIRT031181 | CLIP1 | CAP-Gly domain containing linker protein 1 | 2 | 9 | ||||||||
MIRT031182 | HOXA5 | homeobox A5 | 1 | 1 | ||||||||
MIRT031183 | C16orf70 | chromosome 16 open reading frame 70 | 2 | 5 | ||||||||
MIRT031184 | CYP2U1 | cytochrome P450 family 2 subfamily U member 1 | 2 | 4 | ||||||||
MIRT031185 | CREB3L2 | cAMP responsive element binding protein 3 like 2 | 1 | 2 | ||||||||
MIRT031186 | MTRR | 5-methyltetrahydrofolate-homocysteine methyltransferase reductase | 1 | 1 | ||||||||
MIRT031187 | FAM46A | family with sequence similarity 46 member A | 1 | 1 | ||||||||
MIRT031188 | WBP1L | WW domain binding protein 1 like | 1 | 1 | ||||||||
MIRT031189 | STEAP2 | STEAP2 metalloreductase | 1 | 1 | ||||||||
MIRT031190 | SON | SON DNA binding protein | 1 | 1 | ||||||||
MIRT031191 | AGO1 | argonaute 1, RISC catalytic component | 1 | 2 | ||||||||
MIRT031192 | MBNL1 | muscleblind like splicing regulator 1 | 2 | 5 | ||||||||
MIRT031193 | SLC4A7 | solute carrier family 4 member 7 | 1 | 1 | ||||||||
MIRT031194 | NFIB | nuclear factor I B | 2 | 5 | ||||||||
MIRT031195 | LDLR | low density lipoprotein receptor | 2 | 7 | ||||||||
MIRT031196 | TMEM45A | transmembrane protein 45A | 1 | 1 | ||||||||
MIRT031197 | CEP350 | centrosomal protein 350 | 2 | 6 | ||||||||
MIRT031198 | TRIM33 | tripartite motif containing 33 | 2 | 4 | ||||||||
MIRT031199 | PTPRG | protein tyrosine phosphatase, receptor type G | 2 | 3 | ||||||||
MIRT031200 | FBXO8 | F-box protein 8 | 2 | 3 | ||||||||
MIRT031201 | RNF145 | ring finger protein 145 | 1 | 1 | ||||||||
MIRT031202 | ZER1 | zyg-11 related cell cycle regulator | 1 | 1 | ||||||||
MIRT031203 | ZBTB4 | zinc finger and BTB domain containing 4 | 2 | 7 | ||||||||
MIRT031204 | SYBU | syntabulin | 1 | 1 | ||||||||
MIRT031205 | ARRDC3 | arrestin domain containing 3 | 1 | 2 | ||||||||
MIRT031206 | VPS4B | vacuolar protein sorting 4 homolog B | 1 | 1 | ||||||||
MIRT031207 | C11orf96 | chromosome 11 open reading frame 96 | 1 | 1 | ||||||||
MIRT031208 | SEMA4C | semaphorin 4C | 2 | 8 | ||||||||
MIRT031209 | RAP2C | RAP2C, member of RAS oncogene family | 1 | 2 | ||||||||
MIRT031210 | MYCN | MYCN proto-oncogene, bHLH transcription factor | 1 | 1 | ||||||||
MIRT031211 | SLMAP | sarcolemma associated protein | 1 | 1 | ||||||||
MIRT031212 | SOCS4 | suppressor of cytokine signaling 4 | 1 | 1 | ||||||||
MIRT031213 | RDH11 | retinol dehydrogenase 11 (all-trans/9-cis/11-cis) | 1 | 1 | ||||||||
MIRT031214 | FYCO1 | FYVE and coiled-coil domain containing 1 | 1 | 1 | ||||||||
MIRT031215 | ATMIN | ATM interactor | 2 | 6 | ||||||||
MIRT031216 | C12orf66 | chromosome 12 open reading frame 66 | 1 | 1 | ||||||||
MIRT031217 | NCKAP5 | NCK associated protein 5 | 1 | 1 | ||||||||
MIRT031218 | BTBD3 | BTB domain containing 3 | 1 | 1 | ||||||||
MIRT031219 | SAMD1 | sterile alpha motif domain containing 1 | 1 | 1 | ||||||||
MIRT031220 | WBP2 | WW domain binding protein 2 | 1 | 2 | ||||||||
MIRT031221 | CTR9 | CTR9 homolog, Paf1/RNA polymerase II complex component | 1 | 1 | ||||||||
MIRT031222 | ACPL2 | 2-phosphoxylose phosphatase 1 | 1 | 1 | ||||||||
MIRT031223 | TBC1D13 | TBC1 domain family member 13 | 1 | 1 | ||||||||
MIRT031224 | GPATCH8 | G-patch domain containing 8 | 1 | 1 | ||||||||
MIRT031225 | KIAA1967 | cell cycle and apoptosis regulator 2 | 1 | 1 | ||||||||
MIRT031226 | HNRNPA1 | heterogeneous nuclear ribonucleoprotein A1 | 1 | 1 | ||||||||
MIRT031227 | CD2AP | CD2 associated protein | 1 | 1 | ||||||||
MIRT031228 | SRSF7 | serine and arginine rich splicing factor 7 | 1 | 1 | ||||||||
MIRT031229 | TCF4 | transcription factor 4 | 1 | 1 | ||||||||
MIRT031230 | DAAM2 | dishevelled associated activator of morphogenesis 2 | 1 | 1 | ||||||||
MIRT031231 | HIF1AN | hypoxia inducible factor 1 alpha subunit inhibitor | 1 | 1 | ||||||||
MIRT031232 | HEG1 | heart development protein with EGF like domains 1 | 1 | 1 | ||||||||
MIRT031233 | DCAF8 | DDB1 and CUL4 associated factor 8 | 1 | 1 | ||||||||
MIRT031234 | KLHL21 | kelch like family member 21 | 1 | 1 | ||||||||
MIRT031235 | HABP4 | hyaluronan binding protein 4 | 1 | 1 | ||||||||
MIRT031236 | PDE4D | phosphodiesterase 4D | 1 | 1 | ||||||||
MIRT031237 | SPG20 | spartin | 2 | 6 | ||||||||
MIRT031238 | SAMD8 | sterile alpha motif domain containing 8 | 2 | 3 | ||||||||
MIRT031239 | LTN1 | listerin E3 ubiquitin protein ligase 1 | 1 | 1 | ||||||||
MIRT031240 | MBOAT7 | membrane bound O-acyltransferase domain containing 7 | 1 | 1 | ||||||||
MIRT031241 | RNF41 | ring finger protein 41 | 1 | 1 | ||||||||
MIRT031242 | ARHGAP1 | Rho GTPase activating protein 1 | 2 | 7 | ||||||||
MIRT031243 | ANKRD52 | ankyrin repeat domain 52 | 1 | 1 | ||||||||
MIRT031244 | BTBD10 | BTB domain containing 10 | 1 | 1 | ||||||||
MIRT031245 | ZFAND5 | zinc finger AN1-type containing 5 | 2 | 6 | ||||||||
MIRT031246 | SPTY2D1 | SPT2 chromatin protein domain containing 1 | 1 | 1 | ||||||||
MIRT031247 | LBR | lamin B receptor | 1 | 1 | ||||||||
MIRT031248 | IER3IP1 | immediate early response 3 interacting protein 1 | 1 | 1 | ||||||||
MIRT031249 | WEE1 | WEE1 G2 checkpoint kinase | 1 | 1 | ||||||||
MIRT031250 | TOM1L2 | target of myb1 like 2 membrane trafficking protein | 1 | 1 | ||||||||
MIRT031251 | MEF2D | myocyte enhancer factor 2D | 1 | 1 | ||||||||
MIRT031252 | USP37 | ubiquitin specific peptidase 37 | 2 | 4 | ||||||||
MIRT031253 | ACVR1 | activin A receptor type 1 | 1 | 1 | ||||||||
MIRT031254 | SMYD2 | SET and MYND domain containing 2 | 1 | 1 | ||||||||
MIRT031255 | DCAF7 | DDB1 and CUL4 associated factor 7 | 2 | 4 | ||||||||
MIRT031256 | MREG | melanoregulin | 1 | 1 | ||||||||
MIRT031257 | GFOD1 | glucose-fructose oxidoreductase domain containing 1 | 1 | 1 | ||||||||
MIRT031258 | SEMA6B | semaphorin 6B | 1 | 1 | ||||||||
MIRT031259 | SERINC3 | serine incorporator 3 | 2 | 10 | ||||||||
MIRT031260 | RRAS2 | RAS related 2 | 2 | 2 | ||||||||
MIRT031261 | ESYT1 | extended synaptotagmin 1 | 2 | 3 | ||||||||
MIRT031262 | EPC1 | enhancer of polycomb homolog 1 | 1 | 1 | ||||||||
MIRT031263 | WDR26 | WD repeat domain 26 | 2 | 4 | ||||||||
MIRT031264 | PSAP | prosaposin | 1 | 2 | ||||||||
MIRT031265 | SEL1L3 | SEL1L family member 3 | 1 | 1 | ||||||||
MIRT031266 | JARID2 | jumonji and AT-rich interaction domain containing 2 | 1 | 2 | ||||||||
MIRT031267 | RAB1A | RAB1A, member RAS oncogene family | 2 | 3 | ||||||||
MIRT031268 | RHEBL1 | RHEB like 1 | 1 | 1 | ||||||||
MIRT031269 | CREBL2 | cAMP responsive element binding protein like 2 | 2 | 9 | ||||||||
MIRT031270 | CPPED1 | calcineurin like phosphoesterase domain containing 1 | 1 | 1 | ||||||||
MIRT031271 | STK38 | serine/threonine kinase 38 | 2 | 4 | ||||||||
MIRT031272 | DDX6 | DEAD-box helicase 6 | 2 | 5 | ||||||||
MIRT031273 | SPATA2 | spermatogenesis associated 2 | 2 | 4 | ||||||||
MIRT031274 | CCND2 | cyclin D2 | 2 | 9 | ||||||||
MIRT031275 | CNOT6 | CCR4-NOT transcription complex subunit 6 | 1 | 2 | ||||||||
MIRT031276 | ALG2 | ALG2, alpha-1,3/1,6-mannosyltransferase | 1 | 2 | ||||||||
MIRT031277 | BLCAP | bladder cancer associated protein | 2 | 11 | ||||||||
MIRT031278 | CNOT4 | CCR4-NOT transcription complex subunit 4 | 2 | 6 | ||||||||
MIRT031279 | RASSF2 | Ras association domain family member 2 | 1 | 2 | ||||||||
MIRT031280 | ARHGAP11A | Rho GTPase activating protein 11A | 1 | 1 | ||||||||
MIRT031281 | VAMP3 | vesicle associated membrane protein 3 | 1 | 2 | ||||||||
MIRT031282 | PTPN4 | protein tyrosine phosphatase, non-receptor type 4 | 1 | 1 | ||||||||
MIRT031283 | PRUNE2 | prune homolog 2 | 2 | 3 | ||||||||
MIRT031284 | CPD | carboxypeptidase D | 1 | 1 | ||||||||
MIRT031285 | FAT3 | FAT atypical cadherin 3 | 1 | 1 | ||||||||
MIRT031286 | ZNF521 | zinc finger protein 521 | 1 | 1 | ||||||||
MIRT031287 | CAMSAP1 | calmodulin regulated spectrin associated protein 1 | 2 | 3 | ||||||||
MIRT031288 | TNRC6B | trinucleotide repeat containing 6B | 1 | 2 | ||||||||
MIRT031289 | CGN | cingulin | 1 | 1 | ||||||||
MIRT031290 | IMPDH1 | inosine monophosphate dehydrogenase 1 | 1 | 2 | ||||||||
MIRT031291 | SHCBP1 | SHC binding and spindle associated 1 | 1 | 2 | ||||||||
MIRT031292 | OTUD1 | OTU deubiquitinase 1 | 1 | 2 | ||||||||
MIRT031293 | LPHN2 | adhesion G protein-coupled receptor L2 | 1 | 1 | ||||||||
MIRT031294 | E2F8 | E2F transcription factor 8 | 2 | 4 | ||||||||
MIRT031295 | TAF4 | TATA-box binding protein associated factor 4 | 1 | 2 | ||||||||
MIRT031296 | ATXN7L1 | ataxin 7 like 1 | 1 | 1 | ||||||||
MIRT031297 | ATF2 | activating transcription factor 2 | 1 | 1 | ||||||||
MIRT031298 | SMARCA2 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 | 1 | 2 | ||||||||
MIRT031299 | RNF11 | ring finger protein 11 | 2 | 7 | ||||||||
MIRT031300 | LONRF1 | LON peptidase N-terminal domain and ring finger 1 | 2 | 4 | ||||||||
MIRT031301 | RNF111 | ring finger protein 111 | 1 | 2 | ||||||||
MIRT031302 | HBP1 | HMG-box transcription factor 1 | 2 | 5 | ||||||||
MIRT031303 | KLF10 | Kruppel like factor 10 | 1 | 1 | ||||||||
MIRT050627 | AP2B1 | adaptor related protein complex 2 beta 1 subunit | 1 | 1 | ||||||||
MIRT050628 | TPGS2 | tubulin polyglutamylase complex subunit 2 | 1 | 1 | ||||||||
MIRT050629 | ZNF507 | zinc finger protein 507 | 1 | 1 | ||||||||
MIRT050630 | NCBP2 | nuclear cap binding protein subunit 2 | 1 | 1 | ||||||||
MIRT050631 | ZFHX4 | zinc finger homeobox 4 | 1 | 1 | ||||||||
MIRT050632 | EIF3L | eukaryotic translation initiation factor 3 subunit L | 1 | 1 | ||||||||
MIRT050633 | ALAD | aminolevulinate dehydratase |